# Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

> **NCT04510610** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Camrelizumab and Decitabine

## Key facts

- **NCT ID:** NCT04510610
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510610, "Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04510610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*